HEPA

Hepion Pharmaceuticals, Inc.

1.22 USD
+0.12 (+10.91%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Hepion Pharmaceuticals, Inc. stock is down -1.61% since 30 days ago. The next earnings date is Aug 12, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 45.45% of the previous 10 June’s closed higher than May.

About Hepion Pharmaceuticals, Inc.

Hepion Pharmaceuticals, Inc. focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease.